The blocking of the hERG K+ channels is associated with deadly cardiac arrhythmias (Xue et al., 2022), and the FDA requires that every biomolecule that is considered as a therapeutic candidate be tested for hERG safety before being approved (Supplementary Figure S3). Here, KCNH2 is linked to cardiac rhythm disease.